TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Norwood-Hamilton Type III vertex, IV, or V~Exclusion Criteria:~* History or evidence of hair loss other than androgenetic alopecia~* Scarring of the scalp~* Use of dutasteride in previous 18 months~* Use of finasteride within previous 12 months~* Hair transplantation or hair weaving within 6 months~* Use of Minoxidil within previous 6 months~* Use of drugs with anti-androgenetic/androgenetic properties within previous 6 months~* Use of Drugs that cause hypertrichosis or hypotrichosis within previous 6 months~* Light or laser treatment of scalp within previous 3 months~* Cosmetic products aimed at improving or correcting signs of hair loss within previous 2 weeks

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1mg Finasteride (Type: ACTIVE_COMPARATOR): 1mg finasteride active plus dutasteride placebo, by mouth once daily
- 0.02mg Dutasteride (Type: ACTIVE_COMPARATOR): 0.02mg dutasteride active plus finasteride placebo, by mouth once daily
- 0.1mg Dutasteride (Type: ACTIVE_COMPARATOR): 0.1mg dutasteride active plus finasteride placebo, by mouth once daily
- 0.5mg Dutasteride (Type: ACTIVE_COMPARATOR): 0.5mg dutasteride active plus finasteride placebo, by mouth once daily
- Placebo (Type: PLACEBO_COMPARATOR): 1mg finasteride placebo plus dutasteride placebo, by mouth once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who received gastroscopy for melena, hematochezia, or hematemesis in whom bleeding peptic ulcers with major stigmata of recent hemorrhage are detected are consecutively enrolled. All of these major SRH are treated by local injection of diluted epinephrine 1:10000 with or without combined therapy with a heater probe, argon plasma coagulation, band ligation, or hemoclip therapy.~Exclusion Criteria:~* Patients are excluded if they had tumor bleeding or ulcer bleeding due to mechanical factors (i.e., gastrostomy tube induction), warfarin use, failure to establish hemostasis under gastroscopy, or hypersensitivity to esomeprazole or any component of the formulation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Double oral dose (Type: ACTIVE_COMPARATOR): Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days.
- Regular oral dose (Type: ACTIVE_COMPARATOR): Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
- Control group (Type: ACTIVE_COMPARATOR): Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stepping Stones and Creating Futures Intervention Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Normally resident in informal settlement cluster~* Not formally employed~* Able to communicate in main study languages (English, isiZulu, iXhosa)~Exclusion Criteria:~* Under 18~* Mental deficit (learning difficulty, mental illness or substance abuse)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Stepping Stones and Creating Futures (Type: EXPERIMENTAL): Participants receive the Stepping Stones and Creating Futures intervention, comprising of 21 participatory/inter-active sessions, delivered by a trained facilitators. Each session last approximately 3 hours. Sessions are delivered twice a week. Sessions are primarily single sex, with 20 participants per group.
- Wait-list control (Type: NO_INTERVENTION): Participants receive no intervention until after final data collection occurs, at which point they will be offered Stepping Stones and Creating Futures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* females of infertile couples for whom COS and IVF or ICSI is indicated~* body mass index between 18 and 29 kg/m2~* willing and able to give written informed consent.~Exclusion Criteria:~* More than three previous COS cycles for assisted reproduction since last established ongoing pregnancy (if applicable)~* History of no or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment~* Less than 2 ovaries or any other ovarian abnormality including endometrioma~* Presence of unilateral or bilateral hydrosalpinx~* Any ovarian and/or abdominal abnormality that would interfere with adequate ultrasound investigation of at least one ovary~* History of or current polycystic ovary syndrome (PCOS)~* History of/or current endocrine abnormality~* Any clinically relevant hormone value outside the reference range during the early follicular phase~* Any clinically significant abnormal laboratory value~* Hypertension or currently treated hypertension~* Recent history of current epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary disease~* Alcohol or drug abuse, or history thereof~* Current serious allergic symptoms~* Abnormal cervical smear~* Known hypersensitivity to gonadotropin releasing hormone (GnRH) or its analogs;~* Contra-indications for the use of gonadotropins~* Use of hormonal preparations within 1 month prior to the date of signing consent;~* Administration of any investigational product within 3 months prior to screening.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): ganirelix
- 2 (Type: ACTIVE_COMPARATOR): triptorelin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Previously treated recurrent CLL~* Measurable lymphadenopathy~* Requires therapy for CLL~* Has experienced CLL progression \< 36 months since the completion of the last prior therapy~Key Exclusion Criteria:~* Recent history of a major non-CLL malignancy~* Evidence of an ongoing infection~* CLL refractory to bendamustine~* Concurrent participation in another therapeutic clinical trial~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idelalisib+bendamustine+rituximab (Type: EXPERIMENTAL): Participants will receive idelalisib plus bendamustine and rituximab
- Placebo to match idelalisib+bendamustine+rituximab (Type: PLACEBO_COMPARATOR): Participants will receive placebo to match idelalisib plus bendamustine and rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Caries-arresting Effect of Incorporating fTCP to NaF Varnish Applied Following AgNO3 in Preschool Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* have at least one tooth with cavitated dentine carious lesion~Exclusion Criteria:~* Children have severe forms of dental hypoplasia, under dental treatment or wearing orthodontic devices, have major systemic illness, and are on long-term medication.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- NaF without fTCP (Type: ACTIVE_COMPARATOR): 25% AgNO3 solution followed by 5% NaF.
- NaF with fTCP (Type: EXPERIMENTAL): 25% AgNO3 solution followed by 5% NaF with fTCP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Autologous Peripheral Blood Stem Cell Treatment on Articular Cartilage Regeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have signed informed consent form~* Patients with only unilateral isolated or multiple knee articular cartilage lesions demonstrated MRI scanning, with up to one previous operation on that knee~* Patients who are either male or female aged between 18 to 50 years old, corresponding to availability of normative International Knee Documentation Committee (IKDC) data.~* Female patients of childbearing age must have negative pregnancy tests and are advised to take contraceptive precautions throughout the study.~Exclusion Criteria:~* Patients with bilateral knee lesions~* Patients with the presence of ligamentous injury which would require reconstruction, varus or valgus deformity greater than 10 degrees, previous open total menisectomy requiring osteotomy, and cases that require complex surgery prior to cartilage regeneration~* Patients with significant cognitive impairment, non-ambulatory status or lower extremities amputation other than toes, serious illness or medication affecting operative risk or wound healing (e.g. steroid intake, anticoagulation), and poorly controlled diabetes mellitus with a baseline HbA1c more than 8~* Patients with significant peripheral vascular disease as indicated by absent dorsalis pedis or posterior tibial pulses.~* Patients who cannot read English will be excluded from the study as they will be unable to complete the study questionnaires in an objective manner~* Female patients who are pregnant~* Patients with any contradictions to MRI scanning~* Patients with body mass index (BMI) of over 35

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- PBSC and Hyaluronic Acid (Type: EXPERIMENTAL): Peripheral blood stem cells and hyaluronic acid injections
- Hyaluronic Acid (Type: ACTIVE_COMPARATOR): Hyaluronic Acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glaucoma Biomarkers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Either gender.~* Any self-declared ethnoracial category.~* Greater than or equal to 40 years.~* Healthy eyes with the crystalline lens, without glaucoma (cup:disc ratio \< 0.8 both eyes; asymmetry of cup:disc ratio between eyes \< 0.2).~* Open angles.~* Ability to cooperate for aqueous humor dynamic studies.~* Nonprescription and prescription topical ophthalmic products and systemic medications other than those mentioned in the exclusion criteria will be allowed during the study.~* Contact lenses removed prior to topical fluorescein instillation, and not used until the end of each fluorophotometry session.~* Able to participate on site over the multi-visit study period.~Exclusion Criteria:~* Women who are pregnant due to IOP changes.~* Any form of glaucoma, including extremely narrow angle with complete or partial closure.~* Current use of any glaucoma medication, either topically or orally.~* Chronic or recurrent inflammatory eye disease.~* Ocular trauma within the past 6 months.~* Ocular infection or ocular inflammation in the past 3 months.~* Clinically significant retinal disease.~* Any abnormality preventing reliable fluorophotometry of either eye, such as corneal scarring or severe dry eye that results in punctate fluorescein staining of the cornea.~* Intraocular surgery within 6 months.~* Serious hypersensitivity to any components of the study medications or risk from treatment with glaucoma medications, such as severe asthma or emphysema.~* Subjects must be on a stable regimen for at least 30 days prior to the Visit 1 regarding a chronic systemic medication that may affect IOP (i.e., sympathomimetic agents, beta-blockers, alpha-adrenergic agonists, alpha-adrenergic blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, etc.). Any change of such medication during the study period will result in exclusion.~* Use of any glucocorticoid by any route. Subject must be washed out of the glucocorticoid for at least 2 weeks before study entry.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- timolol (Type: EXPERIMENTAL): To compare the variation in response to timolol between individuals
- latanoprost (Type: ACTIVE_COMPARATOR): To compare the variation in response to latanoprost between individuals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis (MS)~* Patients with a relapsing-remitting disease course~* Patients with Expanded Disability Status Scale (EDSS) score of 0-5.5~Exclusion Criteria:~* Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc~* Pregnant or nursing women~* Patients who cannot tolerate treatment with an interferon~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod 1.25 mg (Type: EXPERIMENTAL): None
- Fingolimod 0.5 mg (Type: EXPERIMENTAL): None
- Interferon β-1a 30 µg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients on the kidney transplant waitlist who have previously undergone desensitization unsuccessfully or in whom effective desensitization will be highly unlikely. The breadth and strength of sensitization will predict an extremely low likelihood of successful desensitization or kidney paired donation.~* Patients with a live or deceased donor with a positive crossmatch test.~Exclusion Criteria:~* Previous treatment with IdeS~* Previous high dose IVIg treatment (2 g/kg BW) within 28 days prior to IdeS treatment~* Lactating or pregnant females~* Women of child-bearing age who are not willing or able to practice FDA-approved forms of contraception~* HIV-positive patients~* Patients with clinical signs of HBV or HCV infection~* Patients with active tuberculosis~* A significantly abnormal general serum screening lab result according to the investigator's judgement. Hgb cannot be \< 6.0 g/dL~* Severe other conditions requiring treatment and close monitoring, e.g. cardiac failure \> NYHA (New York Heart Association) grade 3, unstable coronary disease or oxygen dependent COPD~* Individuals deemed unable to comply with the protocol~* Patients with clinical signs of CMV or EBV infection~* Patients with a history of major thrombotic events, patients with active peripheral vascular disease or patients with proven hypercoagulable conditions~* Patients should not have received investigational drugs within 4 half-lives (or similar)~* Known allergy/sensitivity to IdeS infusions~* Patients who have a live donor and test positive for ImmunoCap anti-IdeS IgE

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment IdeS (Type: EXPERIMENTAL): IdeS intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Donor Human Milk in Neonatal Abstinence Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Term infants (\>37 completed weeks) with a diagnosis of NAS, due to maternal use of opiates (only)~* Infants will have had moderate to severe NAS symptoms (Finnegan scores \>8) that required pharmacologic therapy but have been stabilized (captured) on oral morphine (Finnegan scores less than 8 for 24 hours)~* Breastfeeding is contraindicated or the mother has chosen formula feeding for her baby~Exclusion Criteria:~* Preterm infants (\<37 completed weeks at birth)~* Infants with intrauterine growth restriction (BW \<10th percentile for gestational age)~* Mother is providing her own milk

- Gender: ALL
- Minimum Age: 38 Weeks
- Maximum Age: 42 Weeks
- Healthy Volunteers: f

Study Arms:
- DHM (Type: None): Infants identified with neonatal abstinence syndrome requiring pharmacologic management and who will not be fed own mother's milk

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-~Pregnant Women aged 14 years and over at ≥ 24 weeks' viable gestation who will undergo unscheduled/non-elective cesareans with either:~1. Labor (spontaneous or induced): active labor (ongoing contractions and at least 4cm dilated or contractions for at least 4 hours with documented cervical change of ≥1cm dilatation or ≥50% effacement), or~2. Membrane rupture (standardized to duration of at least 4 hours prior to randomization).~Exclusion Criteria:~* Patient unwilling or unable to provide consent~* Multiple pregnancy~* Known azithromycin (or other macrolide) allergy~* Vaginal delivery~* Elective or scheduled cesarean prior to labor or membrane rupture.~* Azithromycin, erythromycin or other macrolide antibiotic use within 7 days of enrollment.~* Clinical chorioamnionitis or any other active bacterial infection (e.g. pyelonephritis, pneumonia, abscess) at time of randomization.~* Patient is unable or unlikely to follow-up after delivery (e.g. no prenatal care or a non-resident patient)~* Fetal demise or major congenital anomaly~* Significant liver disease defined as known cirrhosis or elevated transaminases of at least 3-fold upper limit of normal~* Significant renal disease defined as serum creatinine known to be \>2.0 mg/dl or on dialysis.~* Active congestive heart failure (EF\<45%) or pulmonary edema~* Active diarrhea at time of delivery~* Any patient with significant electrolyte abnormalities such as hypokalemia or hypocalcemia~* Any patient with structural heart disease or arrhythmias, or taking any medications known to prolong the QT interval~* Patient currently being treated with efavirenz, nelfinavir or fluconazole

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo and standard of care (Type: PLACEBO_COMPARATOR): 250 cc normal saline
- Azithromycin and Standard of care (Type: EXPERIMENTAL): 500 mg Azithromycin in 250 cc normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete